Related Experiment Video
Updated: Jun 8, 2025

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
Published on: February 14, 2018
Antifungal Associations with a Polyelectrolyte Promote Significant Reduction of Minimum Inhibitory Concentrations
Lavínia da V Pereira1,2, Tiago Rizzi1,2, Micaela Federizzi1,2
1Laboratório de Pesquisa Em Micologia Aplicada (LPMA), Universidade Federal Do Rio Grande Do Sul, Rua São Luís 152, Porto Alegre, 90470-440, Brazil.
Abstract:
The current global scenario presents us with a growing increase in infections caused by fungi, referred to by specialists in the field as a "silent epidemic", aggravated by the limited pharmacological arsenal and increasing resistance to this therapy. For this reason, drug repositioning and therapeutic compound combinations are promising strategies to mitigate this serious problem. In this context, this study investigates the antifungal activity of the non-toxic, low-cost and widely available cationic polyelectrolyte Poly(diallyldimethylammonium chloride) (PDDA), in combination with different antifungal drugs: systemic (amphotericin B, AMB), topical (clioquinol, CLIO) and oral (nitroxoline, NTX). For each combination, different drug:PDDA ratios were tested and, through the broth microdilution technique, the minimum inhibitory concentration (MIC) of these drugs in the different ratios against clinically important Candida species strains was determined. Overall, PDDA combinations with the studied drugs demonstrated a significant increase in drug activity against most strains, reaching MIC reductions of up to 512 fold for the fluconazole resistant Candida krusei (Pichia kudriavzevii). In particular, the AMB-PDDA combination 1:99 was highly effective against AMB-resistant strains, demonstrating the excellent profile of PDDA as an adjuvant/association in novel antifungal formulations with outdated conventional drugs.
Insights
This study explored Poly(diallyldimethylammonium chloride) (PDDA) combined with antifungal drugs to combat rising fungal infections. PDDA significantly boosted drug effectiveness, showing promise for new antifungal treatments.
Area of Science:
- Mycology
- Infectious Diseases
- Pharmacology
Background:
- Rising global incidence of fungal infections, termed a "silent epidemic."
- Limited antifungal drug options and increasing drug resistance.
- Drug repositioning and combination therapies offer promising solutions.
Purpose of the Study:
- To investigate the antifungal activity of Poly(diallyldimethylammonium chloride) (PDDA) in combination with existing antifungal drugs.
- To evaluate the efficacy of different drug:PDDA ratios against clinical Candida species.
- To assess PDDA's potential as an adjuvant in novel antifungal formulations.
Main Methods:
- Broth microdilution technique to determine Minimum Inhibitory Concentration (MIC).
- Testing combinations of PDDA with amphotericin B (AMB), clioquinol (CLIO), and nitroxoline (NTX).
- Evaluation against clinically significant Candida species, including resistant strains.
Main Results:
- PDDA combinations significantly enhanced the activity of tested antifungal drugs against most Candida strains.
- MIC reductions up to 512-fold were observed, particularly for fluconazole-resistant Candida krusei.
- The amphotericin B-PDDA combination (1:99 ratio) showed high efficacy against amphotericin B-resistant strains.
Conclusions:
- Poly(diallyldimethylammonium chloride) (PDDA) demonstrates significant potential as an adjuvant to potentiate existing antifungal drugs.
- PDDA-antifungal combinations offer a viable strategy to overcome drug resistance and enhance treatment efficacy.
- This approach could lead to the development of novel, effective antifungal formulations using established drugs.
Related Concept Videos
Antimicrobial Effectiveness
Fungal Group Zygomycota
Combined Effects of Drugs: Synergism
Such synergistic combinations...

